Sirolimus Use in Angioplasty for Vascular Access Extension

NCT01595841

Last updated date
Study Location
London Health Sciences Centre
London, Ontario, N6A 5A5, Canada
Contact
5196858500

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

5196858500

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
End Stage Renal Disease, Venous Stenosis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. A woman who is pregnant or breastfeeding


2. Active malignancy


3. Concomitant treatment with immunosuppressant medications


4. Active infection or treated for infection within the last 30 days


5. Pre-existing interstitial lung disease


6. Thrombocytopenia with platelets less than 100 109/L


7. Previous renal or other solid organ transplant


8. Preexisting liver failure


9. Life expectancy less than 6 months


10. Planned major surgery or major surgery within the last 6 months


11. History of malignancy within the previous 5 years (with the exception of adequately
treated basal cell or squamous cell carcinoma of the skin).


12. Known history of any coronary intervention within the 6 months prior to current
screening


13. Prior or current use of Sirolimus or any of its derivatives within 3 months prior to
angioplasty


14. Active gastrointestinal disorder that may interfere with drug absorption


15. Known to be HIV positive or known active hepatitis B or C infection


16. Treatment with voriconazole, terfenadine, cisapride, astemizole, pimozide, or
ketoconazole (known to interact with Sirolimus) that is not discontinued before
starting Sirolimus treatment.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

End Stage Renal Disease, Venous StenosisSirolimus Use in Angioplasty for Vascular Access Extension
NCT01595841
  1. London, Ontario
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Sirolimus Use in Angioplasty for Vascular Access Extension
Official Title  ICMJE A Randomized Open Label Trial of Oral Sirolimus for Decrease of Stenosis in Arteriovenous Fistula in Hemo-dialysis Patients When Compared With Standard Therapy
Brief Summary Dialysis patients presenting for angioplasty intervention for graft failure will be randomized to receive either Sirolimus or not receive Sirolimus (standard of care) to assess the time from primary failure or angioplasty intervention to second or next angioplasty intervention or graft failure.
Detailed Description This is a randomized control study to determine the feasibility of using sirolimus peri-angioplasty to compare the time from primary failure or angioplasty intervention to second or next angioplasty intervention or graft failure to a control group who would not have received Sirolimus
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE
  • End Stage Renal Disease
  • Venous Stenosis
Intervention  ICMJE Drug: Sirolimus
3 mg po od loading dose for two days, then 2 mg po od for thirty days
Other Name: rapamycin
Study Arms  ICMJE
  • Experimental: Sirolimus
    Participants will take sirolimus for 3 days prior to procedure and 30 days post procedure.
    Intervention: Drug: Sirolimus
  • No Intervention: Not taking Sirolimus
    Participants will not change the standard of care.
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 8, 2012)
36
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE July 2022
Estimated Primary Completion Date July 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion

  1. hemodialysis patients referred for angioplasty for hemodialysis access stenosis through either access flow or clinical monitoring in either an AVF or AVG
  2. > 18 years of age.
  3. Total white blood cell count > 3 x 109 /L and platelet count > 100.0 x 103/uL
  4. Fasting triglycerides < 4.0 mmol/L, fasting cholesterol < 7.8 mmol/L while on optimal lipid lowering therapy.

Exclusion Criteria:

  1. A woman who is pregnant or breastfeeding
  2. Active malignancy
  3. Concomitant treatment with immunosuppressant medications
  4. Active infection or treated for infection within the last 30 days
  5. Pre-existing interstitial lung disease
  6. Thrombocytopenia with platelets less than 100 109/L
  7. Previous renal or other solid organ transplant
  8. Preexisting liver failure
  9. Life expectancy less than 6 months
  10. Planned major surgery or major surgery within the last 6 months
  11. History of malignancy within the previous 5 years (with the exception of adequately treated basal cell or squamous cell carcinoma of the skin).
  12. Known history of any coronary intervention within the 6 months prior to current screening
  13. Prior or current use of Sirolimus or any of its derivatives within 3 months prior to angioplasty
  14. Active gastrointestinal disorder that may interfere with drug absorption
  15. Known to be HIV positive or known active hepatitis B or C infection
  16. Treatment with voriconazole, terfenadine, cisapride, astemizole, pimozide, or ketoconazole (known to interact with Sirolimus) that is not discontinued before starting Sirolimus treatment.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Cindy House5196858500 ext 34769[email protected]
Contact: Samantha Parsons5196858500 ext 34755[email protected]
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01595841
Other Study ID Numbers  ICMJE R-11-774
17839 ( Other Identifier: REB )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Supporting Materials:Study Protocol
Responsible Party Anthony Jevnikar, Lawson Health Research Institute
Study Sponsor  ICMJE Lawson Health Research Institute
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Anthony Jevnikar, MSc MDLawson Health Research Institute
PRS Account Lawson Health Research Institute
Verification Date September 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP